完整後設資料紀錄
DC 欄位語言
dc.contributor.authorLi, Wei-Mingen_US
dc.contributor.authorSu, Chia-Weien_US
dc.contributor.authorChen, Yu-Weien_US
dc.contributor.authorChen, San-Yuanen_US
dc.date.accessioned2015-07-21T08:29:33Z-
dc.date.available2015-07-21T08:29:33Z-
dc.date.issued2015-03-15en_US
dc.identifier.issn1742-7061en_US
dc.identifier.urihttp://dx.doi.org/10.1016/j.actbio.2014.12.013en_US
dc.identifier.urihttp://hdl.handle.net/11536/124508-
dc.description.abstractA co-delivery strategy has been developed to achieve the synergistic effect of a hydrophobic drug (camptothecin, CPT) and a hydrophilic drug (doxorubicin, DOX) by utilizing the unique structure of amphiphilic gelatin/camptothecin @calcium phosphate-doxorubicin (AG/CPT@CaP-DOX) nanoparticles as a carriers in order to replace double emulsions while preserving the advantages of inorganic materials. The hydrophobic agent (CPT) was encapsulated via emulsion with an amphiphilic gelatin core, and subsequently mineralized by CaP-hydrophilic drug (DOX) through precipitation to form a CaP shell on the CPT-AG amphiphilic gelatin core so that drug molecules with different characteristics (i.e. hydrophobic and hydrophilic) can be encapsulated in different regions to avoid their interaction. The existence of the CaP shell can protect the DOX against free release and cause an increased transfer of DOX across membranes, overcoming multidrug resistance. Release studies from core-shell carriers showed the possibility of achieving sequential release of more than one type of drug by controlling the pH-sensitive CaP shell and degradable AG core. The highly pH-responsive behavior of the carrier can modulate the dual-drug-release of DOX/CPT, specifically in acidic intracellular pH environments. The AG/CPT@CaP-DOX nanoparticles also exhibited higher drug efficiencies against MCF-7/ADR cells than MCF-7 cells, thanks to a synergistic cell cycle arrest/apoptosis-inducing effect between CPT and DOX. As such, this core shell system can serve as a general platform for the localized, controlled, sequential delivery of multiple drugs to treat several diseases, especially for multidrug-resistant cancer cells. (C) 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.en_US
dc.language.isoen_USen_US
dc.subjectCalcium phosphateen_US
dc.subjectpH-sensitivityen_US
dc.subjectDrug releaseen_US
dc.subjectAmphiphilic gelatinen_US
dc.subjectMultidrug resistanceen_US
dc.titleIn situ DOX-calcium phosphate mineralized CPT-amphiphilic gelatin nanoparticle for intracellular controlled sequential release of multiple drugsen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.actbio.2014.12.013en_US
dc.identifier.journalACTA BIOMATERIALIAen_US
dc.citation.volume15en_US
dc.citation.spage191en_US
dc.citation.epage199en_US
dc.contributor.department材料科學與工程學系zh_TW
dc.contributor.departmentDepartment of Materials Science and Engineeringen_US
dc.identifier.wosnumberWOS:000350520800019en_US
dc.citation.woscount0en_US
顯示於類別:期刊論文